Literature DB >> 33198594

Immunodominant regions prediction of nucleocapsid protein for SARS-CoV-2 early diagnosis: a bioinformatics and immunoinformatics study.

Yufeng Dai1, Hongzhi Chen2, Siqi Zhuang1, Xiaojing Feng1, Yiyuan Fang1, Haoneng Tang1, Ruchun Dai3, Lingli Tang1, Jun Liu4, Tianmin Ma5, Guangming Zhong6.   

Abstract

COVID-19 caused by SARS-CoV-2 is sweeping the world and posing serious health problems. Rapid and accurate detection along with timely isolation is the key to control the epidemic. Nucleic acid test and antibody-detection have been applied in the diagnosis of COVID-19, while both have their limitations. Comparatively, direct detection of viral antigens in clinical specimens is highly valuable for the early diagnosis of SARS-CoV-2. The nucleocapsid (N) protein is one of the predominantly expressed proteins with high immunogenicity during the early stages of infection. Here, we applied multiple bioinformatics servers to forecast the potential immunodominant regions derived from the N protein of SARS-CoV-2. Since the high homology of N protein between SARS-CoV-2 and SARS-CoV, we attempted to leverage existing SARS-CoV immunological studies to develop SARS-CoV-2 diagnostic antibodies. Finally, N229-269, N349-399, and N405-419 were predicted to be the potential immunodominant regions, which contain both predicted linear B-cell epitopes and murine MHC class II binding epitopes. These three regions exhibited good surface accessibility and hydrophilicity. All were forecasted to be non-allergen and non-toxic. The final construct was built based on the bioinformatics analysis, which could help to develop an antigen-capture system for the early diagnosis of SARS-CoV-2.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antigen-capture diagnostics; linear B-cell epitopes; nucleocapsid protein

Mesh:

Substances:

Year:  2020        PMID: 33198594      PMCID: PMC7678408          DOI: 10.1080/20477724.2020.1838190

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


Introduction

Since the outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 33,249,563 cases of infection and 1,000,040 COVID-19 related deaths have been reported as of 29 September 2020 (https://www.who.int/). A large portion of infected people are asymptomatic, or with only mild symptoms, which pose a major challenge in controlling the COVID-19 pandemic since some asymptomatic patients are still contagious [1]. Thus, early diagnosis and screening of COVID-19 in the large population is urgently needed to contain the pandemic. RT-PCR (short for real-time reverse transcriptase-polymerase chain reaction) is the primary method for the detection of SARS-CoV-2 as well as other respiratory viruses [2,3]. However, RT-PCR requires time-consuming and labor-intensive RNA preparation and professional operation, which increases the difficulty of on-site detection. Antibody testing for SARS-CoV-2 is another option to screen infected patients in the high prevalence areas. As it takes time for hosts to generate antibodies against viruses, antibody detection is suitable for population immunity investigation, but not for early diagnosis [4]. Hence, developing an appropriate antibody for viral antigen detection is highly valuable for the pandemic containment. Structural proteins have been regarded as important targets for antigen detection, such as nucleoprotein of influenza virus, p24 antigen of human immunodeficiency virus (HIV), VP6 of Rotavirus (RV), etc. [5-7]. The coronavirus nucleocapsid (N) protein is a structural protein that plays a critical role in viral RNA replication [8]. According to the studies of severe acute respiratory syndrome coronavirus (SARS-CoV), high levels of circulating N protein in the serum of SARS-CoV patients could be caught as early as clinical symptoms appeared [9]. A comparison of detecting SARS-CoV RNA, specific IgG, and N protein during the early period of illness showed that the detection capability of N protein was notably higher than the other two indicators [10]. These evidences suggested that the N protein could be an appropriate candidate for the early diagnostic testing and screening of SARS-CoV-2. Bioinformatics is a scientific field combining biology, computing, and information technology. It organizes plentiful biological information to systematically and accurately interpret the information from genome transcriptome and proteome. It is extensively applied in immunodiagnostics, immunotherapeutics, and vaccine design [11-13]. Moreover, bioinformatics was used to identify the epitopes of SARS-CoV for raising neutralizing antibodies and diagnostic antibodies in previous studies [14,15]. Given the scarcity of biological data on the antigenic epitopes of SARS-CoV-2, bioinformatics is crucial in the early stages of exploring epitope information. Therefore, we utilized a bioinformatics and immunoinformatics approach to comprehensively deduce the potential immunodominant regions on the N protein of SARS-CoV-2. The complete study workflow is presented in Figure 1. Our study could provide an important complementary strategy in the development of early diagnostic systems to combat the current pandemics.
Figure 1.

Study workflow. First, three linear B-cell epitope prediction tools and one T-cell epitope prediction method were selected to forecast the potential epitopes of SARS-CoV-2 nucleocapsid (N) protein. Second, six bioinformatics tools were applied to evaluate the important characteristics of the predicted regions. Third, potential immunodominant regions were selected for antibody design

Study workflow. First, three linear B-cell epitope prediction tools and one T-cell epitope prediction method were selected to forecast the potential epitopes of SARS-CoV-2 nucleocapsid (N) protein. Second, six bioinformatics tools were applied to evaluate the important characteristics of the predicted regions. Third, potential immunodominant regions were selected for antibody design

Methods

Data retrieval and sequence alignment

N protein sequences of HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43, MERS-CoV, SARS-CoV, and SARS-CoV-2 were downloaded in FASTA format from NCBI database. Sequence alignment of N protein in these seven coronaviruses was performed on EMBL-EBI server Clustal Omega. Clustal Omega exploits seeded guide trees along with HMM profile-profile techniques to produce alignments between multiple sequences [16]. The phylogenetic analysis was also executed to find evolutionary ties among those seven coronaviruses, and the branch length represented the evolutionary distances between two nodes [17].

Linear B-cell epitope prediction

ABCpred, BepiPred-2.0, and Antibody Epitope Prediction online server in the Immune Epitope Database (IEDB) were adopted for linear B-cell epitope prediction. ABCpred server predicts the peptides according to the scores that acquired by the trained recurrent neural network, the higher the peptide score, the higher the prediction accuracy [18]. In our study, the cutoff of ≥0.80 (corresponding to 95.50% specificity) and the length of amino acids of 16 (default window length) of ABCpred server was employed [18]. BepiPred-2.0 server originates a random forest algorithm, which is derived from peptides annotated by antibody-antigen constructions, the residues with scores higher than the threshold are forecasted to be the segment of an epitope. We used a threshold value of ≥0.55 to achieve a specificity of 81.66% for epitope prediction [19]. IEDB is a depository of information associated with epitopes, which provides bioinformatics implements combined with algorithms [20]. The Antibody Epitope Prediction servers were accessible on the B-cell prediction tool page in IEDB, and the threshold was set at 0.35 (default threshold) [20].

Murine T-cell epitope prediction

To forecast murine T-cell epitopes, we utilized the TepiTool resource in IEDB, which employs SMM, ANN, and combinatorial library methods [21]. Here, we set the method as ‘IEDB recommended’. For MHC (Major Histocompatibility Complex) class I binding prediction, the selected model exploits the consensus method comprising of CombLib, ANN, and SMM [22]. In this study, we set predicted consensus percentile rank ≤1 and the length of amino acids to 9. For MHC class II binding prediction, the selected model exploits the consensus method embracing of Sturniolo/Combinatorial Library, NN_align, and SMM_align [23]. The predicted consensus percentile rank ≤10 and 15 residues in length were set.

Profiling and evaluation of predicted epitopes

The selected epitopes were submitted to the VaxiJen v2.0 with the given threshold of 0.40 (corresponding to 70% accuracy) for assessing the antigenic propensity [24]. VaxiJen is an alignment-free method for antigen prediction, it depends on auto cross-covariance (ACC) transformation of protein sequences into uniform vectors of principal amino acid properties, the prediction accuracy is between 70% and 89%. The higher the score, the higher the likelihood to induce immune response [24]. The hydrophilicity was evaluated with ProtScale. We chose the Kyte & Doolittle model as the amino acid scale. This program uses the approach of moving-segment to continuously determine the average hydrophilicity within a segment of a predetermined length in the process of sequence advance [25]. Surface accessibility of predicted peptides was evaluated with the NetsurfP-2.0, which uses an architecture comprised of convolutional along with long short-term memory neural networks trained on solved protein structures to forecast the relative exposure of amino acids [26]. The threshold was set to 25% exposure, but we filtered the regions where RSA (Relative Surface Accessibility) ≥50%. The secondary structure was analyzed by SOPMA. SOPMA has a success rate of 73.2% for a three-state (a-helix, β-sheet, and aperiodic states) description of secondary structure [27]. Toxicity was appraised via the ToxinPred server, which is established on the machine learning technique and quantitative matrix using numerous characters of fragments for forecasting the toxicity. The precision of the dipeptide-based model is 94.50% [28]. Allergenicity was assessed via the AllerTOP v2.0 server, it employs amino acid E-descriptors, auto- and cross-covariance transformation, and some machine learning methods for division [29]. A Protein BLAST search was carried out to determine the possibility of cross-reactivity among the final construct with other proteins. It can yield functional and evolutionary clues about amino acid sequences.

Results

Sequence analysis of N protein in 7 human-related coronaviruses

Human coronavirus (HCoV) includes α-coronaviruses and β-coronaviruses. HCoV-229E and HCoV-NL63 belong to the former, HCoV-HKU1, HCoV-OC43, the Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS-CoV, and the SARS-CoV-2 belong to the latter [30]. N protein is a relatively conservative protein in coronaviruses and has been successfully used as a diagnostic antigen [8,31]. Amino acid sequences of N proteins from these HCoV were obtained from the NCBI database, of which accession IDs were presented in Figure S1A. To better understand the divergence of N protein sequences between SARS-CoV-2 and other HCoVs, Clustal Omega was utilized to compare the full-length N protein sequences of the seven coronaviruses mentioned above. The result revealed that the N protein sequences between SARS-CoV-2 and SARS-CoV are highly similar and the evolutionary relationship of these species based on their N protein sequence information was presented in the phylogenetic tree (Figure S1A & S1B; File S1). As the close homology of N protein between SARS-CoV-2 and SARS-CoV, we analyzed the immunodominant antigenic regions of the SARS-CoV-2 N protein and compared them with the existing immunological studies of SARS-CoV. We abandoned the identical epitopes shared by both to enhance the specificity.

Linear B-cell epitope prediction of SARS-CoV-2 N protein

The full-length sequence of SARS-CoV-2 N protein was evaluated through ABCpred, BepiPred-2.0, and IEDB. The antigenicity was calculated via VaxiJen v2.0 with the given cutoff of ≥0.40. Using the ABCpred algorithm with the threshold value of ≥0.80, we identified 24 peptides (Table S1). Fourteen peptides were obtained via BepiPred-2.0 with a cutoff of ≥0.55 (Table S2). In parallel, a total of 16 peptides were identified by using IEDB (Table S3). The short peptides (less than six amino acids) were discarded. To ensure the specificity, the peptides consistent with the SARS-CoV N protein sequence were excluded. Finally, 11, 8, and 7 potential linear B-cell epitopes forecasted by ABCpred, BepiPred-2.0, and IEDB, respectively, were obtained after stringent filtering (Table 1). After mapping the positions of peptides identified by those three servers, eight regions containing differently predicted epitopes were obtained (Figure 2).
Table 1.

Summary of the linear B-cell epitopes of SARS-CoV-2 nucleocapsid (N) protein predicted via ABCpred, BepiPred-2.0, and IEDB

ToolsSeq#PositionEpitope sequenceLengthScoreAntigenicity
ABCpred191–106TRRIRGGDGKMKDLSP160.941.1467
224–39TGSNQNGERSGARSKQ160.910.6333
3327–342SGTWLTYTGAIKLDDK160.880.9425
459–74HGKEDLKFPRGQGVPI160.870.6163
5182–197ASSRSSSRSRNSSRNS160.870.9557
6376–391ADETQALPQRQKKQQT160.860.6949
777–92NSSPDDQIGYYRRATR160.850.4843
8362–377TFPPTEPKKDKKKKAD160.850.5442
9206–221SPARMAGNGGDAALAL160.830.4517
10334–349TGAIKLDDKDPNFKDQ160.821.8438
11275–290GRRGPEQTQGNFGDQE160.801.2359
Bepipred-2.015–13GPQNQRNAP91.2141
261–67KEDLKFP70.9682
371–81GVPINTNSSPD110.5067
489–104RATRRIRGGDGKMKDL160.8755
5171–213FYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGN430.6201
6229–265QLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTAT370.6878
7361–399KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD390.5321
8408–416QQSMSSADS90.7484
IEDB11–51MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTAS510.4006
258–85QHGKEDLKFPRGQGVPINTNSSPDDQIG280.5570
393–104RIRGGDGKMKDL120.8771
4164–216GTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGD530.5455
5232–269SKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN380.5302
6338–347KLDDKDPNFK102.1298
7361–390KTFPPTEPKKDKKKKADETQALPQRQKKQQ300.5605
Figure 2.

Distribution of predicted B-cell epitope regions, hydrophilic areas and surface accessible regions

Summary of the linear B-cell epitopes of SARS-CoV-2 nucleocapsid (N) protein predicted via ABCpred, BepiPred-2.0, and IEDB Distribution of predicted B-cell epitope regions, hydrophilic areas and surface accessible regions

Profiling and evaluation of hydrophilicity, surface accessibility and secondary structure of selected sequences

To further evaluate the potentiality of these eight antigenic regions as targets for antibody binding, their hydrophilicity, surface accessibility, and secondary structure were analyzed. Eight sequences were forecasted to be hydrophilic via ProtScale (Figure S2A); and when RSA ≥50%, four main regions with good surface accessibility were predicted in NetsurfP-2.0 (Figure S2B). After comparing the predicted peptides with the hydrophilic regions and the surface accessible regions, N58-106, N275-290, and N327-349 were eliminated due to their surface inaccessibility, which might sterically hinder the approachability of antibody (Figure 2). At this point, we obtained five predicted regions (N1-51, N164-221, N229-269, N361-399, N408-416). Considering that structures such as beta-turn and random coil are more conducive to bind with the specific B cell receptor (BCR), we adopted SOPMA online software to predict the secondary structure of N protein (Figure S2C). To ensure the structural integrity of the predicted epitopes, we adjusted the terminus of the selected regions by appropriately adding several amino acid residues at both ends. By synthesizing the results of hydrophilicity, surface accessibility, and secondary structure analysis, we altered N164-221 to N161-221; N361-399 to N354-399. Hereinabove, N1-51, N161-221, N229-269, N354-399, and N408-416 were selected, which contained several potential B-cell epitopes with a high antigenicity score.

Prediction of the murine T-cell epitopes in SARS-CoV-2 N protein

For potential murine T-cell epitopes prediction, the TepiTool resource incorporated in IEDB was utilized. Thirteen peptides of MHC class I binding epitopes along with 16 peptides of MHC class II binding epitopes were identified (Table S4). All predicted T-cell epitopes that overlapped with the selected B-cell epitope regions were displayed in Table S5. Theoretically, MHC-I molecules promote the activation of cytotoxic T lymphocyte (CTL) which kills virus-infected cells [32]. Helper T cells (Th) activated by MHC-II presenting epitopes could provide essential signals to B cells for antibodies production [15]. Predicted murine MHC class II binding epitope N244-258 was included in our predicted B-cell epitope region N229-269; N357-371 and N384-398 were contained in predicted region N354-399; predicted B-cell epitope N408-416 was contained in predicted murine T-cell epitope N405-419. Therefore, N229-269, N354-399, and N405-419 were finally chosen because they contained potential murine MHC class II binding epitopes without murine MHC class I binding epitopes, which makes them more conducive to the production of antibodies. Immunome Browser 3.0 in IEDB comprises the records of existing reference sequences. It can form a response frequency (RF) score to indicate the frequency of the residues in the positive epitopes together with the independent experimental records [33,34]. After scanned in Immunome Browser 3.0, none of the predicted murine MHC class II binding epitopes of SARS-CoV-2 N protein had been confirmed yet. Concurrently, we retrieved the murine MHC class II binding epitopes of SARS-CoV with Immunome Browser 3.0, we found that N351-365 (Epitope ID: 69,035) and N353-365 (Epitope ID: 985,589) in SARS-CoV N protein had been verified as murine MHC class II binding epitopes by experiments [15,35], they corresponded to the identical sequences N350-364 and N352-364 in SARS-CoV-2, respectively. Moreover, we noticed that Val350 and Leu352 were located in an extended strand structure. Thus, to keep the secondary structure integrity, we expanded the predicted region N354-399 to N349-399. Allergenicity of the selected regions was assessed via AllerTOP v2.0, the results demonstrated that all identified regions were predicted to be non-allergen; The toxicity of the three predicted regions was examined by ToxinPred, all of them were forecasted to be non-toxin (Table 2).
Table 2.

Distribution of the potential epitopes and physicochemical properties of the predicted immunodominant regions

N229-269
BepiPred-2.0QLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN
IEDBQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN
TepiToolQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN
HydrophilicityQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN
Surface accessibilityQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN
Secondary structurehhhhhhcccccccttceeehhhhhhhtccccccccccchee
Antigenicity0.5212
AllergenicityNon-allergen
ToxicityNon-toxin
N349-399
BepiPred-2.0QVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
IEDBQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
ABCpredQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
QVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
TepiToolQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
QVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
Verified Mouse-MHC-IIQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
QVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
HydrophilicityQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
Surface accessibilityQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAAD
Secondary structureeeeeehhhhhhhtcccccccccccccccchhccccccccccceeeeccccc
Antigenicity0.4168
AllergenicityNon-allergen
ToxicityNon-toxin
N405-419
BepiPred-2.0KQLQQSMSSADSTQA
TepiToolKQLQQSMSSADSTQA
HydrophilicityKQLQQSMSSADSTQA
Surface accessibilityKQLQQSMSSADSTQA
Secondary structurehhhhhhhhhhccccc
Antigenicity0.4771
AllergenicityNon-allergen
ToxicityNon-Toxin
h, Alpha helix; e, Extended strand; t, Beta turn; c, Random coil.

The predicted epitopes, the hydrophilic regions, and the surface accessible areas were marked in Bold, Italic, and Underlined, respectively.

Distribution of the potential epitopes and physicochemical properties of the predicted immunodominant regions The predicted epitopes, the hydrophilic regions, and the surface accessible areas were marked in Bold, Italic, and Underlined, respectively.

Immunodominant regions selected for recombinant antigen generation

Three predicted regions (N229-269, N349-399, and N405-419) were connected using flexible linkers (GGGGS)2. Flexible linker (GGGGS)2 is excellent in segmenting protein fragments, maintaining biological activity, and promoting protein expression [36]. It had been proved that the Pan DR epitope PADRE (AKFVAAWTLKAAA) functions as a universal T helper epitope, which can induce specific high titer antibodies and lasting antibody responses [37,38]. Hence, we added it to the N-terminal of our construct to boost the humoral immune response (Figure 3). The result of Protein BLAST showed little similarity between the final construct with any known encoded protein, it prompted that the antibody derived from the immune fragment designed in our study is not likely to cross-react with other peptides beyond SARS-CoV-2, which will be confirmed by experiments in the follow-up study.
Figure 3.

Schematic diagram of the selected immunodominant regions and the final construct for designing diagnostic antibodies

Schematic diagram of the selected immunodominant regions and the final construct for designing diagnostic antibodies

Discussion

In this study, we utilized multiple bioinformatics and immunoinformatics approaches to forecast potential immunodominant regions of SARS-CoV-2 N protein. Though several bioinformatic predictions of potential epitopes for SARS-CoV-2 have been reported, these studies mainly focused on vaccine development [33,39-41]. Compared to these studies, we employed distinctive strategies. As we aimed to develop diagnostic antibodies against SARS-CoV-2, mouse was selected as the host species for MHC class II binding epitopes prediction. Additionally, peptides that shared identical sequences with SARS-CoV were excluded to enhance the specificity. Nevertheless, the results of this study were derived from computational algorithms. Whether the antibody can effectively bind to SARS-CoV-2 N protein in clinical samples and the performance of the assay reach the national standard, that is, cross-reactivity, sensitivity, and specificity, remain to be verified by experiments in vitro and in vivo. N protein was reported as a good diagnostic antigen because of its high immunogenicity and affluence during coronavirus infection [8,31]. N protein of the influenza virus is also the main target in antigen-detection tests [42,43]. The influenza antigen detection was useful especially for patients tested within the first 48 hours of illness, when the influenza viral load in the upper respiratory tract was high [44]. Accordingly, we attempted to develop an efficient and accurate N protein-detection assay for SARS-CoV-2. In the follow-up study, newly developed materials such as fluorescent dyes and nanoparticles could be adopted to improve the sensitivity of detection [5]. Influenza virus infection causes respiratory symptoms similar to COVID-19, which makes it difficult to distinguish the diseases by symptoms [45]. Hence, we compared the N protein sequences between the influenza virus and SARS-CoV-2 (File S2). The results showed that the sequence similarity is low, which suggested that direct detection of N protein could distinguish COVID-19 from influenza virus infection. Besides, we noticed that the full-length N protein of SARS-CoV-2 may cross-react with the serum of patients infected with SARS-CoV [4], while truncated protein was proved to reduce the cross-reactivity without reducing sensitivity [46,47]. Hence, we chose to use truncated recombinant protein rather than the full-length N protein for developing diagnostic antibodies. Recently, cladistic studies based on N protein sequence of SARS-CoV-2 have been reported [48-51]. None of the reported mutations are located in the selected immunodominant regions of the current study (data not shown). Nevertheless, attention should be paid to the diagnostic efficiency of mAbs derived from the fragments of SARS-CoV-2 N protein, which need to be evaluated by experiments. SARS-CoV-2 N protein displayed almost the same distribution of hydrophilic regions as that of SARS-CoV N protein, which is easily understood owing to their sequence homology. Yu and colleagues demonstrated that the N122-422 incorporated the main immunogenic sites of the SARS-CoV N protein and could be used for efficient diagnosis [52]. Interestingly, the selected fragments in our study were all located within the corresponding region of SARS-CoV-2 N protein, suggesting an advantage of these fragments in generating optimal diagnostic antibodies. In conclusion, three potential immunodominant regions of SARS-CoV-2 N protein: N229-269, N349-399, and N405-419 that contain both linear B-cell epitopes and murine MHC class II binding epitopes were identified. A construct with 150 amino acids was built (Figure 3). The final construct consists of seven B-cell epitopes, six murine MHC class II binding epitopes, and a PADRE sequence (Table 2). After cloning, expression, and purification of the recombinant protein derived from this study, we will immunize Balb/c mice to generate mAbs with the hybridoma technique. The cross-reactivity, reactivity, specificity, and titer of mAbs will be further evaluated. After confirming the biological functions, these mAbs would be utilized to develop an antigen-capture-based assay system for early diagnosis of SARS-CoV-2. Click here for additional data file.
  51 in total

1.  Prediction of continuous B-cell epitopes in an antigen using recurrent neural network.

Authors:  Sudipto Saha; G P S Raghava
Journal:  Proteins       Date:  2006-10-01

2.  A whole-genome bioinformatics approach to selection of antigens for systematic antibody generation.

Authors:  Lisa Berglund; Erik Björling; Kalle Jonasson; Johan Rockberg; Linn Fagerberg; Cristina Al-Khalili Szigyarto; Asa Sivertsson; Mathias Uhlén
Journal:  Proteomics       Date:  2008-07       Impact factor: 3.984

3.  Peptide binding predictions for HLA DR, DP and DQ molecules.

Authors:  Peng Wang; John Sidney; Yohan Kim; Alessandro Sette; Ole Lund; Morten Nielsen; Bjoern Peters
Journal:  BMC Bioinformatics       Date:  2010-11-22       Impact factor: 3.169

4.  Genomic Variations in SARS-CoV-2 Genomes From Gujarat: Underlying Role of Variants in Disease Epidemiology.

Authors:  Madhvi Joshi; Apurvasinh Puvar; Dinesh Kumar; Afzal Ansari; Maharshi Pandya; Janvi Raval; Zarna Patel; Pinal Trivedi; Monika Gandhi; Labdhi Pandya; Komal Patel; Nitin Savaliya; Snehal Bagatharia; Sachin Kumar; Chaitanya Joshi
Journal:  Front Genet       Date:  2021-03-19       Impact factor: 4.599

5.  IEDB-AR: immune epitope database-analysis resource in 2019.

Authors:  Sandeep Kumar Dhanda; Swapnil Mahajan; Sinu Paul; Zhen Yan; Haeuk Kim; Martin Closter Jespersen; Vanessa Jurtz; Massimo Andreatta; Jason A Greenbaum; Paolo Marcatili; Alessandro Sette; Morten Nielsen; Bjoern Peters
Journal:  Nucleic Acids Res       Date:  2019-07-02       Impact factor: 16.971

Review 6.  Origin and evolution of pathogenic coronaviruses.

Authors:  Jie Cui; Fang Li; Zheng-Li Shi
Journal:  Nat Rev Microbiol       Date:  2019-03       Impact factor: 60.633

7.  Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.

Authors:  Syed Faraz Ahmed; Ahmed A Quadeer; Matthew R McKay
Journal:  Viruses       Date:  2020-02-25       Impact factor: 5.048

8.  Modeling the Onset of Symptoms of COVID-19.

Authors:  Joseph R Larsen; Margaret R Martin; John D Martin; Peter Kuhn; James B Hicks
Journal:  Front Public Health       Date:  2020-08-13

Review 9.  Current Approaches for Diagnosis of Influenza Virus Infections in Humans.

Authors:  Sai Vikram Vemula; Jiangqin Zhao; Jikun Liu; Xue Wang; Santanu Biswas; Indira Hewlett
Journal:  Viruses       Date:  2016-04-12       Impact factor: 5.048

10.  A Distinct Phylogenetic Cluster of Indian Severe Acute Respiratory Syndrome Coronavirus 2 Isolates.

Authors:  Sofia Banu; Bani Jolly; Payel Mukherjee; Priya Singh; Shagufta Khan; Lamuk Zaveri; Sakshi Shambhavi; Namami Gaur; Shashikala Reddy; K Kaveri; Sivasubramanian Srinivasan; Dhinakar Raj Gopal; Archana Bharadwaj Siva; Kumarasamy Thangaraj; Karthik Bharadwaj Tallapaka; Rakesh K Mishra; Vinod Scaria; Divya Tej Sowpati
Journal:  Open Forum Infect Dis       Date:  2020-09-18       Impact factor: 3.835

View more
  7 in total

Review 1.  Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets.

Authors:  Moisés Morais Inácio; Vanessa Rafaela Milhomem Cruz-Leite; André Luís Elias Moreira; Karine Mattos; Juliano Domiraci Paccez; Orville Hernandez Ruiz; James Venturini; Marcia de Souza Carvalho Melhem; Anamaria Mello Miranda Paniago; Célia Maria de Almeida Soares; Simone Schneider Weber; Clayton Luiz Borges
Journal:  Pathogens       Date:  2022-05-11

2.  Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: A structural-dynamics data.

Authors:  Fahad Humayun; Abbas Khan; Sajjad Ahmad; Wang Yuchen; Guoshen Wei; N Nizam-Uddin; Zahid Hussain; Wajid Khan; Nasib Zaman; Muhammad Rizwan; Muhammad Waseem; Dong-Qing Wei
Journal:  Comput Biol Med       Date:  2021-07-31       Impact factor: 6.698

Review 3.  Current and prospective computational approaches and challenges for developing COVID-19 vaccines.

Authors:  Woochang Hwang; Winnie Lei; Nicholas M Katritsis; Méabh MacMahon; Kathryn Chapman; Namshik Han
Journal:  Adv Drug Deliv Rev       Date:  2021-02-06       Impact factor: 17.873

Review 4.  Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms.

Authors:  Maryam Bayat; Yahya Asemani; Sajad Najafi
Journal:  Int Immunopharmacol       Date:  2021-04-15       Impact factor: 5.714

5.  Immunogenomics guided design of immunomodulatory multi-epitope subunit vaccine against the SARS-CoV-2 new variants, and its validation through in silico cloning and immune simulation.

Authors:  Abbas Khan; Shahzeb Khan; Shoaib Saleem; N Nizam-Uddin; Anwar Mohammad; Taimoor Khan; Sajjad Ahmad; Muhammad Arshad; Syed Shujait Ali; Muhammad Suleman; Dong-Qing Wei
Journal:  Comput Biol Med       Date:  2021-04-24       Impact factor: 6.698

6.  Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design.

Authors:  Mohammad Aref Bagherzadeh; Mohammad Izadi; Kazem Baesi; Mirza Ali Mofazzal Jahromi; Majid Pirestani
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

7.  SARS-Arena: Sequence and Structure-Guided Selection of Conserved Peptides from SARS-related Coronaviruses for Novel Vaccine Development.

Authors:  Mauricio Menegatti Rigo; Romanos Fasoulis; Anja Conev; Sarah Hall-Swan; Dinler Amaral Antunes; Lydia E Kavraki
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.